Caution Advised With Upfront SGLT2 Inhibitor-MRA Combo for Heart Failure

By News Health
11 hours Ago

(MedPage Today) — Some heart failure patients had arguably better outcomes after simultaneous initiation of an SGLT2 inhibitor plus a mineralocorticoid receptor antagonist (MRA) in the SOGALDI-PEF trial, but safety markers set off alarms.
In…

Source link : https://www.medpagetoday.com/cardiology/chf/116696

Author :

Publish date : 2025-07-28 18:04:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Here's Who Made This Year's List of Top Hospitals

At Least 60% of Liver Cancers Tied to Preventable Risk Factors

Delivering the World's Most Premature Baby, as Told by the Medical Team

Vaping Up Slightly While Heavy Alcohol Use Down a Little, SAMHSA Report Finds

HTO May Slow Knee OA Progression in Bowlegged Patients

Realignment Surgery Definitely Helps in Knee OA, Trial Indicates